GENFI has built a robust trials platform and developed a number of novel biomarkers for use in clinical trials.
The pilot phase of GENFI ran from 2012 to 2015. It was set up to assess the feasibility of forming a consortium of research centres with an expertise in genetic FTD. The key outcome was the creation of a common methodological platform to study a cohort of individuals affected or at-risk of developing the major genetic forms of FTD, thus allowing tracking of the evolution of genetic FTD from its earliest stages. Funded by a two year Centres of Excellence in Neurodegeneration grant, five centres from the UK, Italy and Canada formed the initial consortium with further centres joining from these countries and also from Sweden and the Netherlands. In total, a cohort of 365 participants was recruited during the pilot phase across thirteen sites.
With the success of the pilot phase of GENFI and confirmation of the feasibility of running a multi-centre genetic FTD study, a five year programme of study started in spring 2015. Further sites joined GENFI2 including centres in Spain, Portugal, France, Belgium and Germany, and over 1000 participants have been recruited across 25 sites. This phase of GENFI has built a robust trials platform and developed a number of novel biomarkers for use in trials.
The next phase of GENFI will start in late 2020 and will focus on developing biomarkers of proximity to symptom onset. We will work closely with the US ALLFTD study within the FTD Prevention Initiative to align the two studies more closely. We will also work with pharmaceutical companies as GENFI participants enter into therapeutic trials.